These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15008365)

  • 1. Control of blood lipids in the elderly.
    Garcia-Palmieri MR
    Bol Asoc Med P R; 2003; 95(5):84-90. PubMed ID: 15008365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary and secondary prevention of cardiovascular disease in the elderly.
    García-Palmieri MR
    Bol Asoc Med P R; 2000; 92(1-3):3-8. PubMed ID: 10846280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
    Alexander KP; Newby LK; Cannon CP; Armstrong PW; Gibler WB; Rich MW; Van de Werf F; White HD; Weaver WD; Naylor MD; Gore JM; Krumholz HM; Ohman EM; ;
    Circulation; 2007 May; 115(19):2549-69. PubMed ID: 17502590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study.
    Ye P; Lu ZL; Du BM; Chen Z; Wu YF; Yu XH; Zhao YC;
    J Am Geriatr Soc; 2007 Jul; 55(7):1015-22. PubMed ID: 17608873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal transplant dysfunction--importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality.
    Soveri I; Holdaas H; Jardine A; Gimpelewicz C; Staffler B; Fellström B
    Nephrol Dial Transplant; 2006 Aug; 21(8):2282-9. PubMed ID: 16574686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins for primary and secondary prevention of coronary heart disease. A scientific review.
    Carneiro AV; Costa J; Borges M
    Rev Port Cardiol; 2004 Jan; 23(1):95-122. PubMed ID: 15058150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of hyperlipidemia in older adults.
    Alexander KP; Blazing MA; Rosenson RS; Hazard E; Aronow WS; Smith SC; Ohman EM
    J Cardiovasc Pharmacol Ther; 2009 Mar; 14(1):49-58. PubMed ID: 19124599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit.
    Ridker PM
    Am Heart J; 2004 Jul; 148(1 Suppl):S19-26. PubMed ID: 15211329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The benefit of cholesterol-lowering medications after coronary revascularization: a population study.
    Brophy JM; Brassard P; Bourgault C
    Am Heart J; 2005 Aug; 150(2):282-6. PubMed ID: 16086931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of preprocedural statin use on procedural myocardial infarction and major cardiac adverse events in percutaneous coronary intervention: a meta-analysis.
    Ebrahimi R; Saleh J; Toggart E; Shah AP; Azmoon S; Babaei H; Lee J; Smith R; Movahed MR; Rubin SA
    J Invasive Cardiol; 2008 Jun; 20(6):292-5. PubMed ID: 18523323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence.
    Preiss D; Sattar N
    Clin Endocrinol (Oxf); 2009 Jun; 70(6):815-28. PubMed ID: 19067719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between plasma lipids and all-cause mortality in nondemented elderly.
    Schupf N; Costa R; Luchsinger J; Tang MX; Lee JH; Mayeux R
    J Am Geriatr Soc; 2005 Feb; 53(2):219-26. PubMed ID: 15673344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender differences in the outcome of cardiac interventions.
    Tillmanns H; Waas W; Voss R; Grempels E; Hölschermann H; Haberbosch W; Waldecker B
    Herz; 2005 Aug; 30(5):375-89. PubMed ID: 16132240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).
    Li JJ; Lu ZL; Kou WR; Chen Z; Wu YF; Yu XH; Zhao YC;
    J Clin Pharmacol; 2009 Aug; 49(8):947-56. PubMed ID: 19602720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cardiovascular risk reduction: impact of an international project].
    Colle B; Brusaferro S;
    Ann Ig; 2008; 20(3 Suppl 1):43-8. PubMed ID: 18773604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.